在心血管疾病之后,癌症是世界上第二致命的恶性肿瘤。本研究旨在通过多层生物信息学方法研究β-肌动蛋白(ACTB)的诊断和预后情况。通过UALCAN分析和验证ACTB的表达,TIMER,GENT2,GEPIA,和HPA。通过MREXPRES评估ACTB启动子甲基化。此外,通过KM绘图仪和TNM图探讨ACTB的预后价值及其与癌症转移的相关性,分别。然后,cBioPortal,CancerSEA,Enrichr,TIMER,MuTarget,和CDT用于分析与ACTB相关的遗传改变,转录因子(TFS),microRNAs(miRNAs),化疗药物,以及其表达之间的相关性,免疫细胞,和不同的其他参数。我们发现ACTB在24种主要人类癌组织中的表达明显高于正常样品。此外,ACTB表达升高仅在肝细胞癌(LIHC)中与较差的生存率和转移有关,头颈部鳞状细胞癌(HNSC),和肺腺癌(LUAD)。这意味着ACTB在LIHC的发展和进展中起着重要作用,HNSC,还有LUAD.此外,富集分析表明,ACTB相关基因调节不同的生物过程(BP),分子功能(MF),和京都基因和基因组百科全书(KEGG)术语。此外,ACTB上调与CD4+T的免疫浸润有有趣的相关性,和CD8+T,肿瘤纯度,突变基因,和其他一些重要的参数。最后,通过这项研究,我们还探索了与ACTB相关的临床重要表达调节剂,包括TFS,miRNA,和不同的化疗药物。本研究的结果表明,ACTB可能是LIHC的潜在候选生物标志物,HNSC,还有LUAD.
After cardiovascular diseases, cancer is the second deadliest malignancy in the world. The current study was launched to investigate the diagnostic and prognostic landscape of Beta-actin (
ACTB) via a multi-layered bioinformatics approach.
ACTB expression was analyzed and validated via UALCAN, TIMER, GENT2, GEPIA, and HPA.
ACTB promoter methylation was evaluated via MREXPRES. Furthermore,
ACTB prognostic values and their correlation with cancer metastasis were explored through the KM plotter and TNMplot, respectively. Then, cBioPortal, CancerSEA, Enrichr, TIMER, MuTarget, and CDT were used to analyze ACTB-related genetic alterations, transcription factors (TFS), MicroRNAs (miRNAs), chemotherapeutic drugs, and the correlation between its expression, immune cells, and different other parameters. We found that
ACTB expression was remarkably higher in 24 major human cancer tissues than the normal samples. Additionally, elevated ACTB expression was associated with poorer survival and metastasis in only liver hepatocellular carcinoma (LIHC), head and neck squamous cancer (HNSC), and lung adenocarcinoma (LUAD). This implies that ACTB plays a significant role in the development and progression of LIHC, HNSC, and LUAD. Furthermore, enrichment analysis showed that ACTB-associated genes regulate different Biological Processes (BP), Molecular Functions (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms. Moreover, ACTB up-regulation had interesting correlations with immune infiltration of CD4+ T, and CD8+ T, tumor purity, mutant genes, and a few other important parameters. At last, via this study, we also explored ACTB-associated clinically important expression regulators, including TFS, miRNAs, and different chemotherapeutic drugs. The results of the present study suggested that ACTB might be a potential candidate biomarker in LIHC, HNSC, and LUAD.